PT2877460T - COMPLEXO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENZIL)-4-(ß-D-GLUCOPIRANOS-1-IL)-BENZENO, MÉTODOS PARA A SUA PREPARAÇÃO E A SUA UTILIZAÇÃO PARA PREPARAR MEDICAMENTOS - Google Patents

COMPLEXO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENZIL)-4-(ß-D-GLUCOPIRANOS-1-IL)-BENZENO, MÉTODOS PARA A SUA PREPARAÇÃO E A SUA UTILIZAÇÃO PARA PREPARAR MEDICAMENTOS

Info

Publication number
PT2877460T
PT2877460T PT13740309T PT13740309T PT2877460T PT 2877460 T PT2877460 T PT 2877460T PT 13740309 T PT13740309 T PT 13740309T PT 13740309 T PT13740309 T PT 13740309T PT 2877460 T PT2877460 T PT 2877460T
Authority
PT
Portugal
Prior art keywords
glucopyranos
cyclopropyl
cyano
benzyl
benzene
Prior art date
Application number
PT13740309T
Other languages
English (en)
Portuguese (pt)
Inventor
Himmelsbach Frank
Eckhardt Matthias
Martin Hans-Juergen
Butz Tanja
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of PT2877460T publication Critical patent/PT2877460T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT13740309T 2012-07-26 2013-07-25 COMPLEXO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENZIL)-4-(ß-D-GLUCOPIRANOS-1-IL)-BENZENO, MÉTODOS PARA A SUA PREPARAÇÃO E A SUA UTILIZAÇÃO PARA PREPARAR MEDICAMENTOS PT2877460T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12177944 2012-07-26

Publications (1)

Publication Number Publication Date
PT2877460T true PT2877460T (pt) 2018-12-19

Family

ID=48874313

Family Applications (2)

Application Number Title Priority Date Filing Date
PT13740309T PT2877460T (pt) 2012-07-26 2013-07-25 COMPLEXO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENZIL)-4-(ß-D-GLUCOPIRANOS-1-IL)-BENZENO, MÉTODOS PARA A SUA PREPARAÇÃO E A SUA UTILIZAÇÃO PARA PREPARAR MEDICAMENTOS
PT181550799T PT3351539T (pt) 2012-07-26 2013-07-25 Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT181550799T PT3351539T (pt) 2012-07-26 2013-07-25 Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt

Country Status (23)

Country Link
US (1) US9145434B2 (enExample)
EP (3) EP3351539B1 (enExample)
JP (2) JP6538556B2 (enExample)
CN (2) CN108774200A (enExample)
AR (1) AR091908A1 (enExample)
AU (1) AU2013294947B2 (enExample)
BR (1) BR112015001327B1 (enExample)
CA (1) CA2878698C (enExample)
DK (2) DK2877460T3 (enExample)
EA (2) EA025438B1 (enExample)
ES (2) ES2937665T3 (enExample)
FI (1) FI3351539T3 (enExample)
HR (2) HRP20181972T1 (enExample)
HU (1) HUE061450T2 (enExample)
LT (1) LT3351539T (enExample)
MX (1) MX357906B (enExample)
PL (2) PL2877460T3 (enExample)
PT (2) PT2877460T (enExample)
RS (1) RS63881B1 (enExample)
SG (1) SG11201500574QA (enExample)
SI (2) SI3351539T1 (enExample)
TW (1) TW201418275A (enExample)
WO (1) WO2014016381A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
EP2981269B9 (en) 2013-04-04 2023-12-06 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
ES2859905T3 (es) * 2013-12-17 2021-10-04 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales felinos
KR20220097538A (ko) * 2014-01-23 2022-07-07 베링거잉겔하임베트메디카게엠베하 개과 동물에서 대사 장애의 치료
PL3125882T3 (pl) 2014-04-01 2020-10-19 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
CN103965020B (zh) * 2014-05-06 2015-09-09 启东东岳药业有限公司 制备5-碘-2-溴苄醇的方法
DK3197429T3 (da) * 2014-09-25 2024-08-26 Boehringer Ingelheim Vetmedica Gmbh Kombinationsbehandling med sglt2-hæmmere og dopaminagonister til forebyggelse af metaboliske lidelser af dyr i hestefamilien
CA2961819C (en) * 2014-09-30 2022-11-08 Jiangsu Hengrui Medicine Co., Ltd. L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound
CZ2015110A3 (cs) * 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
HUE069575T2 (hu) 2015-08-27 2025-03-28 Boehringer Ingelheim Vetmedica Gmbh Folyékony gyógyászati készítmények, amelyek SGLT-2-inhibitorokat tartalmaznak
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
US10793588B2 (en) 2016-05-28 2020-10-06 Ji Lin Hui Sheng Bio-Pharmaceutical Co., Ltd. Crystal form of sodium-glucose cotransporter 2 inhibitor
KR102717283B1 (ko) * 2017-12-19 2024-10-16 베링거잉겔하임베트메디카게엠베하 1-시아노-2-(4-사이클로프로필-벤질)-4-(ß-D-글루코피라노스-1-일)-벤젠, L-프롤린 및 물의 1:1:1 공결정의 합성
UY38969A (es) 2019-11-28 2021-05-31 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
CN118615450A (zh) 2020-02-17 2024-09-10 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
WO2023006747A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
KR20240041966A (ko) 2021-07-28 2024-04-01 베링거잉겔하임베트메디카게엠베하 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
AU2023277704A1 (en) 2022-05-25 2024-12-05 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
US20240307628A1 (en) 2023-03-06 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
WO2024223388A1 (en) 2023-04-24 2024-10-31 Boehringer Ingelheim Vetmedica Gmbh Crystalline complexes between velagliflozin and selected co-crystal forming agents, methods for their preparation and the use thereof for preparing medicaments
AU2024276892A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444481A1 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CN101260130A (zh) * 2003-01-03 2008-09-10 布里斯托尔-迈尔斯斯奎布公司 制备c-芳基葡糖苷sglt2抑制剂的方法
PL1730131T3 (pl) * 2004-03-16 2012-10-31 Boehringer Ingelheim Int Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
BRPI0615882A2 (pt) * 2005-09-08 2011-05-31 Boehringer Ingelheim Int formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
ATE517099T1 (de) * 2006-02-15 2011-08-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
US20080287529A1 (en) * 2007-05-18 2008-11-20 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
CN103319445B (zh) * 2007-12-27 2016-01-20 阿斯利康公司 Sglt2抑制剂的晶体结构及其制备方法
PL2324002T3 (pl) * 2008-08-22 2017-03-31 Theracos Sub, Llc Sposoby otrzymywania inhibitorów sglt2
CN102149717B (zh) 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
WO2010048358A2 (en) 2008-10-22 2010-04-29 Auspex Pharmaceutical, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
EP2981269B9 (en) 2013-04-04 2023-12-06 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals

Also Published As

Publication number Publication date
HRP20230081T1 (hr) 2023-03-17
EA201500038A1 (ru) 2015-07-30
US20140031540A1 (en) 2014-01-30
HUE061450T2 (hu) 2023-07-28
EP2877460A1 (en) 2015-06-03
DK2877460T3 (en) 2019-01-07
CN104470908A (zh) 2015-03-25
WO2014016381A1 (en) 2014-01-30
PL2877460T3 (pl) 2019-04-30
MX2015000962A (es) 2015-04-16
MX357906B (es) 2018-07-30
CA2878698C (en) 2021-03-23
SI3351539T1 (sl) 2023-03-31
EP3351539B1 (en) 2022-11-09
ES2937665T3 (es) 2023-03-30
RS63881B1 (sr) 2023-02-28
PT3351539T (pt) 2023-01-17
TW201418275A (zh) 2014-05-16
CN108774200A (zh) 2018-11-09
EP2877460B1 (en) 2018-09-12
BR112015001327A2 (pt) 2017-07-04
AU2013294947A1 (en) 2015-01-22
LT3351539T (lt) 2023-02-10
BR112015001327B1 (pt) 2022-08-16
PL3351539T3 (pl) 2023-03-06
EA201600506A1 (ru) 2017-03-31
DK3351539T3 (da) 2023-01-30
FI3351539T3 (fi) 2023-02-19
ES2694675T3 (es) 2018-12-26
EP4166548A1 (en) 2023-04-19
EP3351539A1 (en) 2018-07-25
JP6538556B2 (ja) 2019-07-03
JP2018135384A (ja) 2018-08-30
SI2877460T1 (sl) 2018-12-31
AU2013294947B2 (en) 2017-03-30
CA2878698A1 (en) 2014-01-30
US9145434B2 (en) 2015-09-29
AR091908A1 (es) 2015-03-11
HRP20181972T1 (hr) 2019-01-25
EA025438B1 (ru) 2016-12-30
JP2015522644A (ja) 2015-08-06
SG11201500574QA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
SG11201500574QA (en) CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß- D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
IL231386A (en) Pyrazolequinoline derivatives, their preparation and medical use
IL231382A (en) History of benzonitrile, their preparation and medications containing them
PL2930169T3 (pl) Krystaliczna postać chidamidu, sposób jej wytwarzania i zastosowanie
PT2687539T (pt) Variante de anexina v sua preparação e utilização
EP2933250A4 (en) PHENYL-C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF
IL233602A0 (en) History of benzamide, their preparation and pharmaceutical preparations containing them
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL242437B (en) Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process
IL233238A0 (en) Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use
IL239146A0 (en) Aminocyclobutane derivatives, methods for their preparation and their use as drugs
PT2870145T (pt) Derivados de indeno, sua preparação e utilização como medicamentos
EP2929894A4 (en) VACCINE ADJUVANS, PREPARATION AND VACCINES THEREOF
ZA201501597B (en) Macrolide derivatives,preparation thereof and therapeutic use thereof
ZA201407214B (en) Therapeutic preparation and process for preparing said therapeutic preparation
SG11201405376TA (en) CRYSTALLINE FORMS OF 5α-ANDROSTANE-3β, 5, 6β-TRIOL AND PREPARATION METHODS THEREOF
PL398018A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
PL398021A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
GB201112642D0 (en) Surgical hair preparation substance
PL396025A1 (pl) Nowy 7-siarczan 8-prenylonaringeniny i sposób jego wytwarzania
HK1195303A (en) Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
AP2015008270A0 (en) Preparation for the treatment of tuberculosis